Business Description
Panbela Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US86664M2061
Share Class Description:
PBLA: Ordinary SharesDescription
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.5 | |||||
| Equity-to-Asset | -0.4 | |||||
| Debt-to-Equity | -1.1 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 76.6 | |||||
| 3-Year EPS without NRI Growth Rate | 25 | |||||
| 3-Year FCF Growth Rate | 74.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.89 | |||||
| 9-Day RSI | 36.52 | |||||
| 14-Day RSI | 33.33 | |||||
| 6-1 Month Momentum % | -96.12 | |||||
| 12-1 Month Momentum % | -99.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.25 | |||||
| Quick Ratio | 0.25 | |||||
| Cash Ratio | 0.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -746.6 | |||||
| Shareholder Yield % | -1049.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -199.03 | |||||
| ROIC % | -281.22 | |||||
| ROCE % | -893.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.19 | |||||
| EV-to-Forward-EBIT | -0.17 | |||||
| EV-to-EBITDA | -0.19 | |||||
| EV-to-Forward-EBITDA | -0.17 | |||||
| EV-to-FCF | -0.18 | |||||
| Earnings Yield (Greenblatt) % | -526.32 | |||||
| FCF Yield % | -1095.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PBLA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Panbela Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -616.287 | ||
| Beta | 1.61 | ||
| Volatility % | 149.82 | ||
| 14-Day RSI | 33.33 | ||
| 14-Day ATR ($) | 0.128433 | ||
| 20-Day SMA ($) | 0.557618 | ||
| 12-1 Month Momentum % | -99.77 | ||
| 52-Week Range ($) | 0.4 - 476.99999 | ||
| Shares Outstanding (Mil) | 4.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Panbela Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Panbela Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Panbela Therapeutics Inc Frequently Asked Questions
What is Panbela Therapeutics Inc(PBLA)'s stock price today?
The current price of PBLA is $0.47. The 52 week high of PBLA is $477.00 and 52 week low is $0.40.
When is next earnings date of Panbela Therapeutics Inc(PBLA)?
The next earnings date of Panbela Therapeutics Inc(PBLA) is 2024-05-03 Est..
Does Panbela Therapeutics Inc(PBLA) pay dividends? If so, how much?
Panbela Therapeutics Inc(PBLA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers